Compare FDX & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDX | ARGX |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3B | 51.1B |
| IPO Year | N/A | 2017 |
| Metric | FDX | ARGX |
|---|---|---|
| Price | $286.30 | $847.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 19 |
| Target Price | $286.06 | ★ $971.89 |
| AVG Volume (30 Days) | ★ 1.4M | 340.7K |
| Earning Date | 12-18-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ 5.51 | N/A |
| EPS | 17.09 | ★ 23.27 |
| Revenue | ★ $88,591,000,000.00 | $3,683,281,000.00 |
| Revenue This Year | $5.15 | $91.22 |
| Revenue Next Year | $3.93 | $36.36 |
| P/E Ratio | ★ $16.51 | $34.93 |
| Revenue Growth | 1.14 | ★ 92.98 |
| 52 Week Low | $194.30 | $510.06 |
| 52 Week High | $295.24 | $934.62 |
| Indicator | FDX | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 70.47 | 37.51 |
| Support Level | $278.70 | $827.52 |
| Resistance Level | $288.44 | $878.19 |
| Average True Range (ATR) | 5.09 | 17.90 |
| MACD | 0.05 | -9.73 |
| Stochastic Oscillator | 93.47 | 18.94 |
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In fiscal 2025, the firm's Federal Express segment—which houses the core package delivery operations—made up 86% of total revenue, with 10% coming from FedEx Freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.